Entering text into the input field will update the search result below

BeiGene Brukinsa gets approval in Canada for blood cancer subtype

Mar. 03, 2022 7:38 AM ETBeiGene, Ltd. (BGNE)By: Ravikash, SA News Editor

Marginal zone lymphoma, malignant B-cell

OGphoto/iStock via Getty Images

  • BeiGene (NASDAQ:BGNE) medicine Brukinsa was approved by Health Canada to treat adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.
  • The company said it was the third approved

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.